YOLFTbeta
LSL Pharma Group Inc.

LSL Pharma Group Inc.

LSL · V · Healthcare / Drug Manufacturers - Specialty & Generic

0.325CAD+0.04 (+16.07%)

Price History

Full chart

Market Stats

Previous Close0.28
Open0.295
Day Range0.295 – 0.325
52-Week Range0.28 – 0.56
Volume70.50K
Market Cap37.39M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.06
Dividend Yield0.00%
Beta-0.52
50-Day Avg0.3364
200-Day Avg0.3801

About

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. It offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, as well as natural health products in sachets, capsules, loose powder, blister packs, and liquids for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Francois Roberge
  • Employees252
  • Headquarters540, d?Avaugour Street, Boucherville, QC, Canada, J4B 0G6, Canada
  • Websitehttps://www.groupelslpharma.com

Leadership

  • Mr. Francois RobergePresident, CEO & Director · b. 1965
  • Marc BoudreaultVice-President of Communications
  • Mr. Alain R. DugalCOO & Executive VP
  • Mr. Guy Paul AllardVice President, Legal Affairs & Corporate Secretary

Financials

Income Statement

Currency: CAD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.82M8.77M8.21M10.03M17.75M28.74M
Growth (%)-+81.87%-6.35%+22.08%+76.98%+61.96%
Cost of Revenue4.32M6.25M10.39M8.38M12.40M23.64M
Gross Profit507.58K2.53M-2.17M1.65M5.35M5.10M
Gross Margin10.52%28.79%-26.44%16.40%30.13%17.75%
Operating Expense-301.69K2.59M4.58M5.76M4.94M7.41M
Operating Income809.27K-65.27K-6.76M-4.12M406.00K-2.31M
Operating Margin16.78%-0.74%-82.26%-41.05%2.29%-8.04%
EBITDA---5.75M-5.77M6.62M2.29M
EBITDA Margin---69.97%-57.57%37.31%7.95%
Net Income88.01K-1.78M-8.06M-8.47M3.32M-2.82M
Net Income Margin1.82%-20.26%-98.15%-84.48%18.69%-9.81%
R&D--669.00K70.00K--
R&D as % of Total Revenue--8.14%0.70%--
Interest Expense534.96K1.59M1.27M1.57M1.75M2.64M
Interest Expense % of Total Revenue11.09%18.09%15.44%15.66%9.84%9.19%

Balance Sheet

Currency: CAD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets23.79M29.03M27.31M30.90M53.61M74.74M
Total Liabilities16.31M17.92M22.02M22.25M28.72M47.77M
Total Equity7.48M11.11M5.29M8.65M24.89M26.97M
Cash462.13K741.01K08.00K296.00K548.00K
Net Debt8.87M9.13M12.16M13.71M16.47M29.50M

Cash Flow

Currency: CAD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-117.85K-1.08M-3.16M-7.07M-1.65M-2.44M
Financing Cash Flow1.74M940.17K3.42M8.10M9.40M10.15M
Capital Expenditure85.50K914.79K997.00K1.02M4.20M4.96M
Free Cash Flow-203.35K-2.00M-4.16M-8.09M-5.85M-7.40M
Dividends Paid000000
FCF to OCF172.55%184.32%131.51%114.38%354.30%302.78%
Dividend Paid to FCF0.00%0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateNov 18, 2026
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap37.39M
Enterprise Value91.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.89
Price / Book1.90
EPS-0.06
Book Value0.173
Revenue (TTM)41.83M
Gross Profit (TTM)5.17M
EBITDA-1.61M
Profit Margin-17.54%
Operating Margin-7.53%
Return on Equity-31.63%
Return on Assets-3.58%
Shares Outstanding126.73M
Shares Float95.70M
Beta-0.52
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%